These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11361794)

  • 41. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C; Myrto A; Marcelin AG; Ghosn J; Ait-Mohand H; Schneider L; Agher R; Bricaire F; Costagliola D; Calvez V; Peytavin G; Katlama C
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of antiretroviral therapy on hepatitis C viraemia in HIV-infected patients.
    Bravo R; Soriano V; García-Samaniego J; Gómez-Cano M; González-Lahoz J; Altisent C; Ruiz I
    Antivir Ther; 1996 Aug; 1(3):194. PubMed ID: 11322254
    [No Abstract]   [Full Text] [Related]  

  • 45. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 46. Combined protease results continue to hold up.
    McGuire S
    Posit Aware; 1997; 8(1):15. PubMed ID: 11364089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase III results presented on amprenavir triple combination.
    AIDS Patient Care STDS; 1998 Dec; 12(12):941-2. PubMed ID: 11362070
    [No Abstract]   [Full Text] [Related]  

  • 54. Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
    Neth O; Falcon-Neyra L; Ruiz-Valderas R; León Leal JA; Obando I; Alvarez Del Vayo Benito C; Lopez-Cortes LF
    Pediatr Infect Dis J; 2011 Oct; 30(10):917. PubMed ID: 21915022
    [No Abstract]   [Full Text] [Related]  

  • 55. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 56. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E
    Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):5-6. PubMed ID: 15717371
    [No Abstract]   [Full Text] [Related]  

  • 59. HAART therapy: dividing the epidemic?
    Laurence J
    AIDS Patient Care STDS; 1997 Dec; 11(6):397-8. PubMed ID: 11361859
    [No Abstract]   [Full Text] [Related]  

  • 60. Antiviral effect of AZT versus stavudine in combination with lamivudine and indinavir in the context of a populational study.
    Jahnke N; Yip B; Hogg RS; O'Shaughnessy M; Montaner JS
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):347-8. PubMed ID: 10428115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.